From: Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
Grade 3/4 AEs(reported in ≥3% of patients)
AA group
Prednisone-alone group
ALT increased
11.6% (5 of 43)
11.8% [2 of 17]
Hypokalaemia
9.3% (4 of 43)
Hyperglycaemia
4.7% (2 of 43)
5.9% [1 of 17]